970*90
768
468
mobile

Lupin gets EIR from USFDA for Pithampur Manufacturing Unit

Franchise India Bureau
Franchise India Bureau Apr 06 2018 - 1 min read
Lupin gets EIR from USFDA for Pithampur Manufacturing Unit
In November last, Lupin had received warning letter from USFDA (US Food and Drug Administration) for its manufacturing facilities in Goa and Pithampur.

Drug firm Lupin has confirmed to have received an Establishment Inspection Report (EIR) from the US health regulator for its Pithampur, Unit 1 manufacturing facility in Madhya Pradesh.

The inspection was conducted in July 2017, it said in a BSE filing.

USFDA gives EIR on the closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.

In November last, Lupin had received a warning letter from USFDA (US Food and Drug Administration) for its manufacturing facilities in Goa and Pithampur.

The stock of Lupin was trading at Rs 812.60, up 3.38 percent, from the previous close on BSE.

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online